Liesl K. Janssens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liesl K. Janssens has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Christophe Pol Stove
Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
6 shared publications - Annelies Cannaert
Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
2 shared publications - Paul Ivor Dargan
Clinical Toxicology Guy's and St Thomas' NHS Foundation Trust London UK
2 shared publications - Andrea Eva Steuer
Department of Forensic Pharmacology and Toxicology, Institute of Forensic Medicine University of Zurich Zurich Switzerland
1 shared publication - Bernard De Baets
KERMIT, Department of Data Analysis and Mathematical Modelling, Ghent University, Gent, Belgium
1 shared publication - Caitlin M. Wolfe
World Health Organization Regional Office for Africa, B.P. 06 Cité de Djoué, Brazzaville, Congo; University of South Florida College of Public Health, 13201 Bruce B Downs Boulevard, Tampa, FL 33612, USA
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by Wiley in Drug Testing and Analysis
Retrospective Study on the Power and Interpretation of Chiral Amphetamine Analysis in Hair for Forensic Applications
Chiral amphetamine analysis is performed in forensic toxicology to determine the nature of amphetamine intake (therapeutic or illicit). It is crucial to the correct interpretation of amphetamine‐positive hair samples in terms of abstinence control and therapy compliance, where hair analysis is used to evaluate the average amphetamine use over a period of several months. However, interpretative challenges arise when different medication intakes and/or illicit drug consumption events contribute to the hair analysis result. Therefore, a retrospective study of authentic casework was conducted (2017–2025, n = 340) to assess the performance of chiral amphetamine analysis in hair and to enhance the interpretation of its results. Two liquid chromatography tandem mass spectrometry (LC–MS/MS) based methods were used and compared, based on chiral derivatization (i.e., indirect method) or a chiral stationary phase (i.e., direct method). Chiral analysis results are expressed as enantiomeric fractions (EF) of ( S )‐amphetamine in hair. Chiral analysis results in hair were interpreted as in accordance with therapy compliance (e.g., Elvanse or Attentin) (EF ≥ 0.95, n = 284) or illicit amphetamine use (EF ≤ 0.55, n = 32). Between these proposed cut‐offs, the results were indicative of combined use of medical and illicit amphetamine or of therapeutic use of mixed amphetamine salts products (e.g., Adderall) (0.55 < EF < 0.95, n = 24). It was shown that segmented hair analysis can be beneficial for the interpretation of such indicative results. This retrospective study shows that chiral amphetamine analysis in hair confidently distinguishes between (sole) therapeutic and (sole) illicit amphetamine use and has established a decision model for the interpretation of EFs in hair for forensic casework.
- 15 October 2026
- Published by Wiley in Drug Testing and Analysis
Open AccessRetrospective Study on the Power and Interpretation of Chiral Amphetamine Analysis in Hair for Forensic Applications
Chiral amphetamine analysis is performed in forensic toxicology to determine the nature of amphetamine intake (therapeutic or illicit). It is crucial to the correct interpretation of amphetamine‐positive hair samples in terms of abstinence control and therapy compliance, where hair analysis is used to evaluate the average amphetamine use over a period of several months. However, interpretative challenges arise when different medication intakes and/or illicit drug consumption events contribute to the hair analysis result. Therefore, a retrospective study of authentic casework was conducted (2017–2025, n = 340) to assess the performance of chiral amphetamine analysis in hair and to enhance the interpretation of its results. Two liquid chromatography tandem mass spectrometry (LC–MS/MS) based methods were used and compared, based on chiral derivatization (i.e., indirect method) or a chiral stationary phase (i.e., direct method). Chiral analysis results are expressed as enantiomeric fractions (EF) of ( S )‐amphetamine in hair. Chiral analysis results in hair were interpreted as in accordance with therapy compliance (e.g., Elvanse or Attentin) (EF ≥ 0.95, n = 284) or illicit amphetamine use (EF ≤ 0.55, n = 32). Between these proposed cut‐offs, the results were indicative of combined use of medical and illicit amphetamine or of therapeutic use of mixed amphetamine salts products (e.g., Adderall) (0.55 < EF < 0.95, n = 24). It was shown that segmented hair analysis can be beneficial for the interpretation of such indicative results. This retrospective study shows that chiral amphetamine analysis in hair confidently distinguishes between (sole) therapeutic and (sole) illicit amphetamine use and has established a decision model for the interpretation of EFs in hair for forensic casework.
- 10 August 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 229, 116478
The ‘ABC’ of split-nanoluciferase HIF heterodimerization bioassays: Applications, Benefits & Considerations
- 10 August 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 229, 116478
The ‘ABC’ of split-nanoluciferase HIF heterodimerization bioassays: Applications, Benefits & Considerations
- 8 August 2024
- Published by Springer Nature in Archives of Toxicology
- Vol. 98 (10) , 3337-3350
Interpreting mono- and poly-SCRA intoxications from an activity-based point of view: JWH-018 equivalents in serum as a comparative measure
Synthetic cannabinoid receptor agonists (SCRAs) are a class of synthetic drugs that mimic and greatly surpass the effect of recreational cannabis. Acute SCRA intoxications are in general difficult to assess due to the large number of compounds involved, differing widely in both chemical structure and pharmacological properties. The rapid pace of emergence of unknown SCRAs hampers on one hand the timely availability of methods for identification and quantification to confirm and estimate the extent of the SCRA intoxication. On the other hand, lack of knowledge about the harm potential of emerging SCRAs hampers adequate interpretation of serum concentrations in intoxication cases. In the present study, a novel comparative measure for SCRA intoxications was evaluated, focusing on the cannabinoid activity (versus serum concentrations), which can be measured in serum extracts with an untargeted bioassay assessing ex vivo CB1 activity. Application of this principle to a series of SCRA intoxication cases (n = 48) allowed for the determination of activity equivalents, practically entailing a conversion from different SCRA serum concentrations to a JWH-018 equivalent. This allowed for the interpretation of both mono- (n = 34) and poly-SCRA (n = 14) intoxications, based on the intrinsic potential of the present serum levels to exert cannabinoid activity (cf. pharmacological/toxicological properties). A non-distinctive toxidrome was confirmed, showing no relation to CB1 activity. The JWH-018 equivalent was partly related to the poison severity score (PSS) and causality of the clinical intoxication elicited by the SCRA. Altogether, this equivalent concept allows to comparatively and timely interpret (poly-)SCRA intoxications based on CB1 activity.
- 8 August 2024
- Published by Springer Nature in Archives of Toxicology
- Vol. 98 (10) , 3337-3350
Interpreting mono- and poly-SCRA intoxications from an activity-based point of view: JWH-018 equivalents in serum as a comparative measure
Synthetic cannabinoid receptor agonists (SCRAs) are a class of synthetic drugs that mimic and greatly surpass the effect of recreational cannabis. Acute SCRA intoxications are in general difficult to assess due to the large number of compounds involved, differing widely in both chemical structure and pharmacological properties. The rapid pace of emergence of unknown SCRAs hampers on one hand the timely availability of methods for identification and quantification to confirm and estimate the extent of the SCRA intoxication. On the other hand, lack of knowledge about the harm potential of emerging SCRAs hampers adequate interpretation of serum concentrations in intoxication cases. In the present study, a novel comparative measure for SCRA intoxications was evaluated, focusing on the cannabinoid activity (versus serum concentrations), which can be measured in serum extracts with an untargeted bioassay assessing ex vivo CB1 activity. Application of this principle to a series of SCRA intoxication cases (n = 48) allowed for the determination of activity equivalents, practically entailing a conversion from different SCRA serum concentrations to a JWH-018 equivalent. This allowed for the interpretation of both mono- (n = 34) and poly-SCRA (n = 14) intoxications, based on the intrinsic potential of the present serum levels to exert cannabinoid activity (cf. pharmacological/toxicological properties). A non-distinctive toxidrome was confirmed, showing no relation to CB1 activity. The JWH-018 equivalent was partly related to the poison severity score (PSS) and causality of the clinical intoxication elicited by the SCRA. Altogether, this equivalent concept allows to comparatively and timely interpret (poly-)SCRA intoxications based on CB1 activity.
- 12 May 2024
- Published by Springer Nature in Archives of Toxicology
- Vol. 98 (8) , 2619-2630
Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays—and how this matters for the harm potential of seized drugs
Cultivation of industrial low-Δ9-tetrahydrocannabinol (Δ9-THC) hemp has created an oversupply of cannabidiol (CBD)-rich products. The fact that phytocannabinoids, including CBD, can be used as precursors to synthetically produce a range of THC variants—potentially located in a legal loophole—has led to a diversification of cannabis recreational drug markets. ‘Hemp-compliant’, ‘hemp-derived’ and ‘semisynthetic’ cannabinoid products are emerging and being advertised as (legal) alternatives for Δ9-THC. This study included a large panel (n = 30) of THC isomers, homologs, and analogs that might be derived via semisynthetic procedures. As a proxy for the abuse potential of these compounds, we assessed their potential to activate the CB1 cannabinoid receptor with a β-arrestin2 recruitment bioassay (picomolar–micromolar concentrations). Multiple THC homologs (tetrahydrocannabihexol, THCH; tetrahydrocannabiphorol, THCP; tetrahydrocannabinol-C8, THC-C8) and THC analogs (hexahydrocannabinol, HHC; hexahydrocannabiphorol, HHCP) were identified that showed higher potential for CB1 activation than Δ9-THC, based on either higher efficacy (Emax) or higher potency (EC50). Structure–activity relationships were assessed for Δ9-THC and Δ8-THC homologs encompassing elongated alkyl chains. Additionally, stereoisomer-specific differences in CB1 activity were established for various THC isomers (Δ7-THC, Δ10-THC) and analogs (HHC, HHCP). Evaluation of the relative abundance of 9(S)-HHC and 9(R)-HHC epimers in seized drug material revealed varying epimeric compositions between batches. Increased abundance of the less active 9(S)-HHC epimer empirically resulted in decreased potency, but sustained efficacy for the resulting diastereomeric mixture. In conclusion, monitoring of semisynthetic cannabinoids is encouraged as the dosing and the relative composition of stereoisomers can impact the harm potential of these drugs, relative to Δ9-THC products.
- 12 May 2024
- Published by Springer Nature in Archives of Toxicology
- Vol. 98 (8) , 2619-2630
Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays—and how this matters for the harm potential of seized drugs
Cultivation of industrial low-Δ9-tetrahydrocannabinol (Δ9-THC) hemp has created an oversupply of cannabidiol (CBD)-rich products. The fact that phytocannabinoids, including CBD, can be used as precursors to synthetically produce a range of THC variants—potentially located in a legal loophole—has led to a diversification of cannabis recreational drug markets. ‘Hemp-compliant’, ‘hemp-derived’ and ‘semisynthetic’ cannabinoid products are emerging and being advertised as (legal) alternatives for Δ9-THC. This study included a large panel (n = 30) of THC isomers, homologs, and analogs that might be derived via semisynthetic procedures. As a proxy for the abuse potential of these compounds, we assessed their potential to activate the CB1 cannabinoid receptor with a β-arrestin2 recruitment bioassay (picomolar–micromolar concentrations). Multiple THC homologs (tetrahydrocannabihexol, THCH; tetrahydrocannabiphorol, THCP; tetrahydrocannabinol-C8, THC-C8) and THC analogs (hexahydrocannabinol, HHC; hexahydrocannabiphorol, HHCP) were identified that showed higher potential for CB1 activation than Δ9-THC, based on either higher efficacy (Emax) or higher potency (EC50). Structure–activity relationships were assessed for Δ9-THC and Δ8-THC homologs encompassing elongated alkyl chains. Additionally, stereoisomer-specific differences in CB1 activity were established for various THC isomers (Δ7-THC, Δ10-THC) and analogs (HHC, HHCP). Evaluation of the relative abundance of 9(S)-HHC and 9(R)-HHC epimers in seized drug material revealed varying epimeric compositions between batches. Increased abundance of the less active 9(S)-HHC epimer empirically resulted in decreased potency, but sustained efficacy for the resulting diastereomeric mixture. In conclusion, monitoring of semisynthetic cannabinoids is encouraged as the dosing and the relative composition of stereoisomers can impact the harm potential of these drugs, relative to Δ9-THC products.
- Open Access
- 14 August 2022
- Published by Elsevier in Toxicologie Analytique et Clinique
- Vol. 34 (3) , S51
Large-scale activity-based SCRA screening on patient serum samples: CB1 bioassay supported by machine learning
- 14 August 2022
- Published by Elsevier in Toxicologie Analytique et Clinique
- Vol. 34 (3) , S51
Open AccessLarge-scale activity-based SCRA screening on patient serum samples: CB1 bioassay supported by machine learning
- 12 August 2022
- Published by Springer Nature in Archives of Toxicology
- Vol. 96 (11) , 2935-2945
Linking in vitro and ex vivo CB1 activity with serum concentrations and clinical features in 5F-MDMB-PICA users to better understand SCRAs and their metabolites
Synthetic cannabinoid receptor agonists (SCRAs) pose a danger to public health. This study focused on individuals experiencing recreational drug toxicity who had used 5F-MDMB-PICA. Patient records were evaluated regarding vital signs, Glasgow Coma Scale (GCS) and clinical features. Liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS) confirmed and quantified the presence of 5F-MDMB-PICA (and/or metabolites) as the only SCRA present in the serum of 71 patients. Cannabinoid activity was evaluated by a cannabinoid receptor (CB1) bioassay, to assess the relationship between serum concentrations and ex vivo human CB1 activation potential. Furthermore, a link with the clinical presentation was appraised. 5F-MDMB-PICA and five metabolites were pharmacologically profiled in vitro, revealing theoretically possible contributions of two active in vivo metabolites to overall cannabinoid activity. Serum concentrations of 5F-MDMB-PICA were correlated to the ex vivo cannabinoid activity, revealing a sigmoidal relationship. The latter could also be predicted based on pharmacological characterization of 5F-MDMB-PICA and its metabolites and an in-depth investigation of the bioassay outcome. Clinically, the GCS showed a significant trend (decrease) with increasing ex vivo cannabinoid activity. This is the first study to evaluate possible toxic effects of 5F-MDMB-PICA in a unique large patient cohort. It allows a better understanding of 5F-MDMB-PICA and metabolites in humans, suggesting a negligible contribution by 5F-MDMB-PICA metabolites to the overall cannabinoid activity in serum. Additionally, this work shows that in vitro pharmacological characterization allows close prediction of an individual’s ex vivo CB1 activity, the latter showing a relationship with the level of consciousness.
- 12 August 2022
- Published by Springer Nature in Archives of Toxicology
- Vol. 96 (11) , 2935-2945
Linking in vitro and ex vivo CB1 activity with serum concentrations and clinical features in 5F-MDMB-PICA users to better understand SCRAs and their metabolites
Synthetic cannabinoid receptor agonists (SCRAs) pose a danger to public health. This study focused on individuals experiencing recreational drug toxicity who had used 5F-MDMB-PICA. Patient records were evaluated regarding vital signs, Glasgow Coma Scale (GCS) and clinical features. Liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS) confirmed and quantified the presence of 5F-MDMB-PICA (and/or metabolites) as the only SCRA present in the serum of 71 patients. Cannabinoid activity was evaluated by a cannabinoid receptor (CB1) bioassay, to assess the relationship between serum concentrations and ex vivo human CB1 activation potential. Furthermore, a link with the clinical presentation was appraised. 5F-MDMB-PICA and five metabolites were pharmacologically profiled in vitro, revealing theoretically possible contributions of two active in vivo metabolites to overall cannabinoid activity. Serum concentrations of 5F-MDMB-PICA were correlated to the ex vivo cannabinoid activity, revealing a sigmoidal relationship. The latter could also be predicted based on pharmacological characterization of 5F-MDMB-PICA and its metabolites and an in-depth investigation of the bioassay outcome. Clinically, the GCS showed a significant trend (decrease) with increasing ex vivo cannabinoid activity. This is the first study to evaluate possible toxic effects of 5F-MDMB-PICA in a unique large patient cohort. It allows a better understanding of 5F-MDMB-PICA and metabolites in humans, suggesting a negligible contribution by 5F-MDMB-PICA metabolites to the overall cannabinoid activity in serum. Additionally, this work shows that in vitro pharmacological characterization allows close prediction of an individual’s ex vivo CB1 activity, the latter showing a relationship with the level of consciousness.
- 3 June 2020
- Published by Wiley in Drug Testing and Analysis
- Vol. 12 (9) , 1336-1343
In vitro activity profiling of Cumyl‐PEGACLONE variants at the CB1 receptor: Fluorination versus isomer exploration
Synthetic cannabinoid receptor agonists (SCRAs) are one of the largest groups of new psychoactive substances monitored in Europe. SCRAs are known to typically exert higher cannabinoid activity than tetrahydrocannabinol from cannabis, thereby entailing a greater health risk. Both Cumyl‐PEGACLONE and 5F‐Cumyl‐PEGACLONE were not controlled by the national legislation upon their first detection in Germany in 2016 and 2017, respectively, and have been linked to several fatalities. In this study, the CB1 receptor activity of these compounds, together with two newly synthesized structural isomers (Cumyl‐PEGACLONE ethylbenzyl isomer and n‐propylphenyl isomer), was assessed using two different in vitro receptor‐proximal bioassays, monitoring the recruitment of either β‐arrestin2 (β‐arr2) or a modified G protein (mini‐Gαi) to the activated CB1 receptor. In terms of both potency and relative efficacy, Cumyl‐PEGACLONE and 5F‐Cumyl‐PEGACLONE were found to exert strong CB1 activation, with sub‐nanomolar EC50 values and efficacy values exceeding those of the reference agonist JWH‐018 threefold (β‐arr2 assay) or almost twofold (mini‐Gαi assay). The ethylbenzyl and n‐propylphenyl isomers exhibited a strongly reduced CB1 activity (EC50 values >100 nM; efficacy 1 activation potential and that the ethylbenzyl and n‐propylphenyl isomers yield a strongly reduced CB1 activation.
- 3 June 2020
- Published by Wiley in Drug Testing and Analysis
- Vol. 12 (9) , 1336-1343
In vitro activity profiling of Cumyl‐PEGACLONE variants at the CB1 receptor: Fluorination versus isomer exploration
Synthetic cannabinoid receptor agonists (SCRAs) are one of the largest groups of new psychoactive substances monitored in Europe. SCRAs are known to typically exert higher cannabinoid activity than tetrahydrocannabinol from cannabis, thereby entailing a greater health risk. Both Cumyl‐PEGACLONE and 5F‐Cumyl‐PEGACLONE were not controlled by the national legislation upon their first detection in Germany in 2016 and 2017, respectively, and have been linked to several fatalities. In this study, the CB1 receptor activity of these compounds, together with two newly synthesized structural isomers (Cumyl‐PEGACLONE ethylbenzyl isomer and n‐propylphenyl isomer), was assessed using two different in vitro receptor‐proximal bioassays, monitoring the recruitment of either β‐arrestin2 (β‐arr2) or a modified G protein (mini‐Gαi) to the activated CB1 receptor. In terms of both potency and relative efficacy, Cumyl‐PEGACLONE and 5F‐Cumyl‐PEGACLONE were found to exert strong CB1 activation, with sub‐nanomolar EC50 values and efficacy values exceeding those of the reference agonist JWH‐018 threefold (β‐arr2 assay) or almost twofold (mini‐Gαi assay). The ethylbenzyl and n‐propylphenyl isomers exhibited a strongly reduced CB1 activity (EC50 values >100 nM; efficacy 1 activation potential and that the ethylbenzyl and n‐propylphenyl isomers yield a strongly reduced CB1 activation.